Back to search page

rdkr20170427001

EUROSTARS: An effective new medicine for treatment of atopy root cause

RESEARCH PROFILE   REQUEST   ADD TO FAVOURITES
PRINT

 

ABSTRACT

A South Korean SME specialized in developing a new medicine and companion diagnostics has developed a medicine to treat atopy. They are currently looking for companies in expertise of medical trial to co-develop this integrated system in the context of a EUROSTARS project.


FULL DESCRIPTION

A Korean SME expertise in the development of new medicines is seeking partners to cooperate in the Eurostars2 project. They have a creative platform that shows the best processor and efficiency. The company also has reliable clinical test methods. They have developed a new medicine for atopy treatment.

The developed medicine is acting as an inhibitor for the initial inflammatory process. It is an oral and percutaneous medicine effective for radical cure. Currently, it is finished developing and processed the clinical trial: phase 2. It is proved that the developed medicine has higher efficacy than steroid in Atopic Dermatitis(AD). It is targeting to Thymic stromal lymphopoietin (TSLP) production and able to cure the fundamental cause of atopy. Also, it can be synthesized simply and the cost for synthesis process is not expensive.

They company is looking for clinical trial, new medicine development, atopy treatment expertise. The company is willing to cooperate in research and development of the medicine. The target market would be increased to 9 billion dollars in 2020. The partners are expected to cooperate in developing the integrated system.

Deadline for EOI: 1 August 2017
Deadline for Call: 14 September 2017
Project duration: 104 weeks


Partner expertise sought:

- Specific area of activity of the partner: Type of partner sought
- R&D institute, University, SME and Larger company
Specific area of activity of partner
- Clinical trial, new medicine development, atopy treatment
Tasks to be performed by the partner sought
- Research cooperation: Cooperate in R&D of the treatment of atopy root cause


Advantages & innovations:

- Targeting to TSLP production
- Higher efficacy than steroid in AD
- Topical and oral treatment route
- Non-toxic in oral and topical treatment
- Simple and cost-effective synthesis


Development Stage:

Field tested/evaluated - Clinical trial - Phase 2

Sign-in or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here

KEY INFORMATION

Country of origin
SOUTH KOREA
Profile date
13/06/2017
Deadline
13/06/2018

PARTNERSHIP(S) SOUGHT

Research cooperation agreement

CLASSIFICATIONS

INDUSTRY SECTORS
Industrial Manufacture \ Life Sciences \ Chemistry & Chemical Engineering \ Biosciences and Health \ Drug Discovery and Drug Development \ Medical Devices
TECHNOLOGY KEYWORDS
BIOLOGICAL SCIENCES / Medicine, Human Health / Clinical Research, Trials / BIOLOGICAL SCIENCES / Medicine, Human Health / Medical Research / BIOLOGICAL SCIENCES / Medicine, Human Health / Pharmaceutical Products / Drugs
COMMERCIAL KEYWORDS
Manufacture of basic pharmaceutical products / Manufacture of pharmaceutical preparations
MARKET KEYWORDS
MEDICAL/HEALTH RELATED / Clinical Medicine / Allergy research / MEDICAL/HEALTH RELATED / Clinical Medicine / Internal medicine / MEDICAL/HEALTH RELATED / Clinical Medicine / Other clinical medicine

FIND OUT MORE

Contact Enterprise Europe Network Scotland by email at info@enterprise-europe-scotland.com, quoting reference number rdkr20170427001